Drug Utilization Review (DUR) Meeting Minutes
December 3, 2012

Members Present: Norman Byers, John Savageau, Russ Sobotta, Tanya Schmidt, Leann Ness, David Clinkenbeard, Carrie Sorenson, Cheryl Huber, Carlotta McCleary, James Carlson, Greg Pfister, Michael Booth, Jeffrey Hostetter

Members Absent: Steve Irsfeld, Todd Twogood

Medicaid Pharmacy Department: Brendan Joyce

HID Staff Present: Candace Rieth

Chair G. Pfister called the meeting to order at 1:00 pm. Chair G. Pfister asked for a motion to approve the minutes from the September meeting. N. Byers moved that the minutes be approved and D. Clinkenbeard seconded the motion. Chair G. Pfister called for a voice vote to approve the minutes. The motion passed with no audible dissent. Dr. Michael Booth has filled the open position on the DUR Board. Introductions were made.

Budget Update
B. Joyce informed the board members that there is no new information from fiscal since the last board meeting. B. Joyce also informed the board that the rebate owed to the government by the state is larger than was originally anticipated.

Actinic Keratosis Second Review
A motion and second were made at the September meeting to place agents used to treat Actinic Keratosis on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

Moxeza Second Review
A motion and second were made at the September meeting to place Moxeza on prior authorization. The topic was brought up for a second review. There was no public comment. Chair G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent. Moxeza will be added to the ophthalmic anti-infective form.

Patients Taking Multiple Long-Acting Narcotics Second Review
B. Joyce reviewed recipients taking multiple long-acting narcotics and Oxycontin three times daily. After discussion, the board agreed that edits should be put in to place to decrease the chance of diversion and to improve patient care.

Yearly PA Review
The Board reviews products annually that have previously been placed on prior authorization. This allows the Board a chance to update the prior authorization forms and criteria. All forms and criteria were reviewed. Changes include:

1. ACE-I/ARB/Renin Inhibitors PA form – M. Booth made a motion to remove losartan from prior authorization. C. Huber seconded the motion. There was no public comment. Motion passed with no audible dissent.
2. Gilenya – Add specialist involved in therapy to form.
3. Livalo – J. Hostetter made a motion to require adequate dosing of existing generics (simvastation/atorvastatin) for 3 months or side effects as criteria for coverage. C. Sorenson seconded the motion. There was no public comment. Motion passed with no audible dissent.

4. Nuedexta – Add 'specialist involved in therapy' to form.
5. Metozolv – Add to ODT form.
6. Oral Anticoagulants – Update form and criteria with new indications.
7. Solodyn – Add to Doryx/Oracea form
8. Soma 250 – Add to Carisoprodol form.

Kathleen Karnick, representing Janssen, spoke about Nucynta and Nucynta ER. Randy Troxell, representing Novartis, spoke about Gilenya and ACE-I/ARB/Renin Inhibitor prior authorization.

Genitourinary Smooth Muscle Relaxants Review
B. Joyce reviewed genitourinary smooth muscle relaxants (GSM) clinical information and data with the Board. There was no public comment. After discussion, N. Byers made a motion to place GSMs on prior authorization. T. Schmidt seconded the motion. This topic will be brought up at the next meeting for finalization.

Agents Used to Treat Multiple Sclerosis (MS) Review
B. Joyce reviewed Aubagio clinical information and data with the Board. There was no public comment. After discussion, J. Hostetter made a motion to place Aubagio on prior authorization. D. Clinkenbeard seconded the motion. This topic will be brought up at the next meeting for finalization.

Criteria Recommendations
The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and usually are consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria, and will be used in future DUR cycles. C. Huber moved to approve the new criteria and D. Clinkenbeard seconded the motion. Chair G. Pfister called for a voice vote. The motion passed with no audible dissent.

The next DUR board meeting will be held March 11th, 2013 in Bismarck. N. Byers made a motion to adjourn the meeting. G. Pfister seconded. The motion passed with no audible dissent. G. Pfister adjourned the meeting.